Article
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Antimicrobial agents and chemotherapy - 1 Feb 2018
Krishnan Preethi, Schnell Gretja, Tripathi Rakesh, Beyer Jill, Reisch Thomas, Dekhtyar Tatyana, Irvin Michelle, Xie Wangang, Fu Bo, Burroughs Margaret, Redman Rebecca, Kumada Hiromitsu, Chayama Kazuaki, Collins Christine, Pilot-Matias Tami
Abstract excerpt
Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose combination regimen demonstrated high sustained virologic response 12 weeks postdosing (SVR12) rates in CERTAIN-1 and CERTAIN-2 studies in Japanese HCV-infected patients, with a low virologic failure rate (1.2%). There were no virologic failures among...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.